트랜스티레틴 아밀로이드증 치료제 시장 : 유형별, 질환별, 약물 유형별, 투여 경로별, 유통 채널별 - 세계 예측(2024-2032년)

Transthyretin amyloidosis treatment market size is expected to witness 7.5% CAGR between 2024 and 2032, driven by the advancements in medical research and technologies. Lately, several therapeutic innovations are offering promising outcomes in halting disease progression and improving patient outcomes. The increasing awareness and diagnosis rate of transthyretin amyloidosis, particularly in regions with aging population will contribute to the market expansion. For instance, the worldwide occurrence of hereditary transthyretin-mediated (hATTR) is likely to affect roughly 50,000 individuals, showcasing diverse symptoms depending on the organs affected.

Moreover, there have also been collaborations between pharmaceutical companies and research institutions to facilitate the development of new drugs and therapies by leveraging combined expertise and resources to accelerate the discovery process. Growing regulatory approvals for novel treatments and the expansion of reimbursement coverage for transthyretin amyloidosis therapies will further enhance the accessibility of treatment options.

The transthyretin amyloidosis treatment industry is divided into type, disease type, drug type, route of administration, distribution channel, and region.

With respect to route of administration, the market size from the parenteral segment is slated to depict 7.8% CAGR between 2024 to 2032, due to the efficacy and convenience in delivering therapeutic agents directly into the bloodstream. Parenteral method ensures rapid and consistent drug absorption, bypassing gastrointestinal degradation and variability associated with oral administration. For patients with transthyretin amyloidosis, who often experience gastrointestinal symptoms and malabsorption issues, parenteral administration offers a reliable means of delivering therapeutic agents effectively.

Based on distribution channel, the transthyretin amyloidosis treatment market from the online pharmacy segment will record 8% growth rate through 2032. These channels provide a convenient platform for individuals to purchase prescription medications and specialty treatments, including those for transthyretin amyloidosis, from the comfort of their homes. This accessibility is particularly beneficial for patients residing in remote areas and those with mobility limitations, who may face challenges accessing traditional brick-and-mortar pharmacies.

Europe transthyretin amyloidosis treatment market size will exhibit 7.8% CAGR through 2032, attributed to increasing investments in healthcare infrastructure and research initiatives focused on rare diseases. European countries are prioritizing healthcare advancements and allocating substantial resources to support innovative therapies and treatment modalities. Additionally, regulatory agencies have implemented expedited approval pathways and incentives to encourage the development of orphan drugs, further stimulating the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of transthyretin amyloidosis cases
    • 3.2.1.2 Development of novel therapies
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Advancements in diagnostics techniques
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited treatment options
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 ATTR amyloidosis with polyneuropathy (ATTR-PN)
• 5.3 ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hereditary transthyretin amyloidosis
  • 6.2.1 Polyneuropathy
  • 6.2.2 Cardiomyopathy
  • 6.2.3 Mixed type
• 6.3 Wild type transthyretin amyloidosis

Chapter 7 Market Estimates and Forecast, By Drug type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Tafamidis
• 7.3 Patisiran
• 7.4 Inotersen
• 7.5 Other drug types

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail drug stores
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Acrotech Biopharma, LLC
• 11.2 Alnylam Pharmaceuticals, Inc.
• 11.3 AstraZeneca PLC
• 11.4 Astellas Pharma Inc.
• 11.5 BridgeBio Pharma, Inc.
• 11.6 Bristol-Myers Squibb Company
• 11.7 Ionis Pharmaceuticals, Inc.
• 11.8 Johnson & Johnson
• 11.9 Prothena Biosciences Limited
• 11.10 Pfizer Inc.
• 11.11 SOM Innovation Biotech, S.L.